UTAH MEDICAL PRODUCTS INC (UTMD) Stock Fundamental Analysis
USA - NASDAQ:UTMD - US9174881089 - Common Stock
58.1 USD
+1.5 (+2.65%)
Overall UTMD gets a fundamental rating of 6 out of 10. We evaluated UTMD against 189 industry peers in the Health Care Equipment & Supplies industry. UTMD scores excellent points on both the profitability and health parts. This is a solid base for a good stock. UTMD is valued correctly, but it does not seem to be growing.
1. Profitability
1.1 Basic Checks
UTMD had positive earnings in the past year.
UTMD had a positive operating cash flow in the past year.
UTMD had positive earnings in each of the past 5 years.
UTMD had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
With an excellent Return On Assets value of 10.39%, UTMD belongs to the best of the industry, outperforming 93.12% of the companies in the same industry.
UTMD has a Return On Equity of 10.68%. This is amongst the best in the industry. UTMD outperforms 86.24% of its industry peers.
Looking at the Return On Invested Capital, with a value of 8.80%, UTMD belongs to the top of the industry, outperforming 87.83% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for UTMD is above the industry average of 9.02%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.39% | ||
| ROE | 10.68% | ||
| ROIC | 8.8% |
ROA(3y)12.3%
ROA(5y)11.87%
ROE(3y)13.06%
ROE(5y)12.7%
ROIC(3y)12.32%
ROIC(5y)12.29%
1.3 Margins
The Profit Margin of UTMD (32.33%) is better than 96.30% of its industry peers.
In the last couple of years the Profit Margin of UTMD has grown nicely.
Looking at the Operating Margin, with a value of 32.51%, UTMD belongs to the top of the industry, outperforming 98.94% of the companies in the same industry.
UTMD's Operating Margin has been stable in the last couple of years.
Looking at the Gross Margin, with a value of 57.33%, UTMD is in line with its industry, outperforming 56.08% of the companies in the same industry.
In the last couple of years the Gross Margin of UTMD has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 32.51% | ||
| PM (TTM) | 32.33% | ||
| GM | 57.33% |
OM growth 3Y-0.06%
OM growth 5Y0.46%
PM growth 3Y4%
PM growth 5Y1.55%
GM growth 3Y-2.17%
GM growth 5Y-1.24%
2. Health
2.1 Basic Checks
UTMD has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, UTMD has less shares outstanding
UTMD has less shares outstanding than it did 5 years ago.
There is no outstanding debt for UTMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
UTMD has an Altman-Z score of 37.28. This indicates that UTMD is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of UTMD (37.28) is better than 97.35% of its industry peers.
There is no outstanding debt for UTMD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 37.28 |
ROIC/WACC1.01
WACC8.75%
2.3 Liquidity
UTMD has a Current Ratio of 41.87. This indicates that UTMD is financially healthy and has no problem in meeting its short term obligations.
UTMD has a better Current ratio (41.87) than 100.00% of its industry peers.
UTMD has a Quick Ratio of 38.22. This indicates that UTMD is financially healthy and has no problem in meeting its short term obligations.
UTMD has a better Quick ratio (38.22) than 100.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 41.87 | ||
| Quick Ratio | 38.22 |
3. Growth
3.1 Past
The earnings per share for UTMD have decreased strongly by -13.65% in the last year.
Measured over the past 5 years, UTMD shows a small growth in Earnings Per Share. The EPS has been growing by 0.16% on average per year.
UTMD shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -16.65%.
Measured over the past years, UTMD shows a decrease in Revenue. The Revenue has been decreasing by -2.70% on average per year.
EPS 1Y (TTM)-13.65%
EPS 3Y-0.66%
EPS 5Y0.16%
EPS Q2Q%-3.95%
Revenue 1Y (TTM)-16.65%
Revenue growth 3Y-5.87%
Revenue growth 5Y-2.7%
Sales Q2Q%-4.3%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 15.53, the valuation of UTMD can be described as correct.
UTMD's Price/Earnings ratio is rather cheap when compared to the industry. UTMD is cheaper than 85.71% of the companies in the same industry.
When comparing the Price/Earnings ratio of UTMD to the average of the S&P500 Index (26.11), we can say UTMD is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.53 | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, UTMD is valued cheaply inside the industry as 95.77% of the companies are valued more expensively.
94.18% of the companies in the same industry are more expensive than UTMD, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.52 | ||
| EV/EBITDA | 6.72 |
4.3 Compensation for Growth
UTMD has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)100.07
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
UTMD has a Yearly Dividend Yield of 2.16%.
UTMD's Dividend Yield is rather good when compared to the industry average which is at 1.89. UTMD pays more dividend than 96.83% of the companies in the same industry.
UTMD's Dividend Yield is comparable with the S&P500 average which is at 2.37.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.16% |
5.2 History
The dividend of UTMD has a limited annual growth rate of 1.95%.
UTMD has paid a dividend for at least 10 years, which is a reliable track record.
UTMD has decreased its dividend in the last 3 years.
Dividend Growth(5Y)1.95%
Div Incr Years2
Div Non Decr Years2
5.3 Sustainability
32.72% of the earnings are spent on dividend by UTMD. This is a low number and sustainable payout ratio.
The dividend of UTMD is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP32.72%
EPS Next 2YN/A
EPS Next 3YN/A
NASDAQ:UTMD (10/31/2025, 8:18:02 PM)
58.1
+1.5 (+2.65%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners71.57%
Inst Owner Change-0.51%
Ins Owners7.13%
Ins Owner Change-0.27%
Market Cap186.50M
Revenue(TTM)38.83M
Net Income(TTM)12.55M
Analysts0
Price TargetN/A
Short Float %3.82%
Short Ratio12.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 2.16% |
Yearly Dividend1.22
Dividend Growth(5Y)1.95%
DP32.72%
Div Incr Years2
Div Non Decr Years2
Ex-Date
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 15.53 | ||
| Fwd PE | N/A | ||
| P/S | 4.8 | ||
| P/FCF | 13.52 | ||
| P/OCF | 13.2 | ||
| P/B | 1.59 | ||
| P/tB | 1.84 | ||
| EV/EBITDA | 6.72 |
EPS(TTM)3.74
EY6.44%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)4.3
FCFY7.4%
OCF(TTM)4.4
OCFY7.58%
SpS12.1
BVpS36.61
TBVpS31.58
PEG (NY)N/A
PEG (5Y)100.07
Graham Number55.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.39% | ||
| ROE | 10.68% | ||
| ROCE | 10.65% | ||
| ROIC | 8.8% | ||
| ROICexc | 28.7% | ||
| ROICexgc | 51.67% | ||
| OM | 32.51% | ||
| PM (TTM) | 32.33% | ||
| GM | 57.33% | ||
| FCFM | 35.54% |
ROA(3y)12.3%
ROA(5y)11.87%
ROE(3y)13.06%
ROE(5y)12.7%
ROIC(3y)12.32%
ROIC(5y)12.29%
ROICexc(3y)38.7%
ROICexc(5y)33.39%
ROICexgc(3y)78.49%
ROICexgc(5y)75.65%
ROCE(3y)14.9%
ROCE(5y)14.86%
ROICexgc growth 3Y-5.7%
ROICexgc growth 5Y-2.21%
ROICexc growth 3Y5.77%
ROICexc growth 5Y9.65%
OM growth 3Y-0.06%
OM growth 5Y0.46%
PM growth 3Y4%
PM growth 5Y1.55%
GM growth 3Y-2.17%
GM growth 5Y-1.24%
F-Score6
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 11.49% | ||
| Cap/Sales | 0.86% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 91.04% | ||
| Profit Quality | 109.9% | ||
| Current Ratio | 41.87 | ||
| Quick Ratio | 38.22 | ||
| Altman-Z | 37.28 |
F-Score6
WACC8.75%
ROIC/WACC1.01
Cap/Depr(3y)10.06%
Cap/Depr(5y)9.94%
Cap/Sales(3y)1.14%
Cap/Sales(5y)1.32%
Profit Quality(3y)119.58%
Profit Quality(5y)135.38%
High Growth Momentum
Growth
EPS 1Y (TTM)-13.65%
EPS 3Y-0.66%
EPS 5Y0.16%
EPS Q2Q%-3.95%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-16.65%
Revenue growth 3Y-5.87%
Revenue growth 5Y-2.7%
Sales Q2Q%-4.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.15%
EBIT growth 3Y-5.93%
EBIT growth 5Y-2.25%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-38.35%
FCF growth 3Y-10.92%
FCF growth 5YN/A
OCF growth 1Y-38.83%
OCF growth 3Y-11.23%
OCF growth 5Y-2.76%
UTAH MEDICAL PRODUCTS INC / UTMD FAQ
What is the ChartMill fundamental rating of UTAH MEDICAL PRODUCTS INC (UTMD) stock?
ChartMill assigns a fundamental rating of 6 / 10 to UTMD.
What is the valuation status for UTMD stock?
ChartMill assigns a valuation rating of 5 / 10 to UTAH MEDICAL PRODUCTS INC (UTMD). This can be considered as Fairly Valued.
Can you provide the profitability details for UTAH MEDICAL PRODUCTS INC?
UTAH MEDICAL PRODUCTS INC (UTMD) has a profitability rating of 8 / 10.
What is the valuation of UTAH MEDICAL PRODUCTS INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for UTAH MEDICAL PRODUCTS INC (UTMD) is 15.53 and the Price/Book (PB) ratio is 1.59.